Husam A. Ghanim PhD

Husam Ghanim

Husam A. Ghanim
PhD

Contact Information
875 Ellicott Street
Buffalo, New York 14203
Phone: 716-881-8924
Fax: 716-639-1200
ghanim@buffalo.edu



Education and Training:

  • PhD, State University of New York at Buffalo (2004)
  • BS, University of Jordan

Employment:

  • UB-IRB Committee member, University at Buffalo (2018-present)
  • Research Director, Medicine, Division of Endocrinology, Diabetes and Metabolism (2005-present)
  • Research Associate Professor, Endocrinology, State University of New York at Buffalo Jacobs School of Medicine & Biomedical Sciences (2014-present)

Awards and Honors:

  • Internal Medicine Training Program Teaching appreciation award (2013)
  • The Pharmacia Corporation International Award for Excellence in Published Clinical Research (2001)

Grants and Sponsored Research:

  • January 2019–December 2024
    Triple therapy for T1DM with insulin, semaglutide and dapagliflozin
    JDRF
    Role: Co-Principal Investigator
    $1,641,000
  • January 2018–December 2024
    An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes
    AstraZeneca Pharmaceuticals LP
    Role: Co-Investigator
    $735,000
  • September 2022–June 2024
    3- Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple Daily Injection Therapy
    Lilly
    Role: Co-Investigator
    $258,000
  • December 2023–May 2024
    3- A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP)
    GSK
    Role: Contributor
    $25,200
  • September 2022–April 2024
    2- A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Display Injections
    Lilly
    Role: Co-Investigator
    $283,500
  • December 2021–December 2022
    Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment
    CTSI
    Role: Principal Investigator
    $50,000
  • July 2021–July 2022
    LIGHT-UP Study service contract
    Gelesis Inc
    Role: Contributor
    $371,000
  • December 2012–November 2019
    Effects of liraglutide treatment in overweight or obese patients with type 1 diabetes
    JDRF
    Role: Co-Investigator
    $600,000
  • August 2012–July 2017
    Liraglutide as an Additional treatment in Type 1 diabetes
    NIH/NIDDK
    Role: Co-Investigator
    $1,580,000
  • May 2024
    1- A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes, Moderate or Severe Renal Impairment with Inadequate Glycemic Control on Basal Insulin with or without Metformin and/or SGLT2 inhibitor (TRANSCEND-T2D-3)
    Lilly
    Role: Co-Investigator
    $315,000
  • May 2024
    1- Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism
    AbbVie
    Role: Co-Investigator
    $340,200
  • January 2023
    3- NATiV3: A randomized, double blind, placebo-controled, multicentre, Phase 3 study evaluating long term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis.
    Inventiva
    Role: Contributor
    $245,700
See all (2 more)

Journal Articles:

See all (99 more)

Professional Memberships:

  • The Obesity Society; Member (2019–present)
  • American Diabetes Association; Professional Membership
  • Endocrine Society; Member

Presentations:

  • "New Advancements in Weight Managment" CME/ Catholic Health Ground Rounds (2024)
  • "How much can people with type 1 diabetes benefit from adjunct therapies?" 58th Annual European Association for the Study of Diabetes (2022)
  • "Weight loss and body composition: Relevance to Weight Regain" Virtual CME Saturday (2022)
  • "Weight Loss in Older Obese Patients: The Obesity Paradox" Grand Round (2022)

Service Activities:

  • Endocrine Research; Assocaite Editor (2024–present)
  • Awards of Excellence for Promoting Inclusion and Cultural Diversity.; Reviewer (2024)
  • Medical Students Annual Reseach Forum. Review, judge and rank posters of medical students; Reviewer and Judge (2024)
  • Peace Center of WNY; Volunteer (2023–present)
  • FY24 Training Awards Review, JDRF; Reviewer (2023)
  • Review, interview and rank applicants for fellowship position every year; reviewer (2023)
  • Reivew applicant's CV's and patriciate in interviews and ranking; Chief of Nephrology search committee (2023–2024)
  • JDRF FY22 Beta Improving Lives Training AWARD; REVIEWER (2021)
  • Reviewer for Journal of Cellular and Molecular Medicine; Reviewer (2021–present)
  • CTSI Translational Pilot Studies Program; Reviewer (2020)
  • Reviewer for Diabetes, Obesity and Metabolism; Reviewer (2020–present)
  • Discussion group to improve IRB function. Chair: Dr Sanjay Sethi; IRB working group (2019)
  • DOM Research Day abstract reviewer and poster Judge. Research performed by residents, fellows and junior faculty; Abstract Reviewer (2019–present)
  • Reviewer for The Journal of Clinical Endocrinology & Metabolism; Reviewer (2019–present)
  • Islamic Society of Niagara Frontier Sunday School Board president; Sunday School Board president (2018–present)
  • I have been a member of the review committee in UBIRB since 2018. Received excellent evaluation for my role and re-appointed for 3 more years till 2027; IRB review board member (2018–present)
  • Research Staff and volunteer's supervisor. Signing time sheets, assign duties and allocating effort; Research Staff and volunteer's supervisor (2006–present)
  • Member of Network of Religious Communities. Supporting peace and understanding in the WNY area; Community Representative
  • Provide general and specific research guidance for resident and fellows in the department and division; Endocrine Division Research Director

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

875 Ellicott Street
Buffalo, New York 14203
Phone: 716-881-8924
Fax: 716-639-1200
ghanim@buffalo.edu